An Open-Label, Multicenter, Multinational Study to Assess the Safety,Tolerability and Pharmacokinetics of Aerosolized Amikacin Delivered Via the Pulmonary Drug Delivery System (NKTR-061) in Intubated and Mechanically- Ventilated Patients With Nosocomial Pneumonia.
Phase of Trial: Phase II
Latest Information Update: 19 Feb 2016
At a glance
- Drugs Amikacin (Primary)
- Indications Gram-negative infections; Nosocomial pneumonia
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Bayer
- 17 Feb 2016 According to ClinicalTrials.gov record,primary end points has been revised.
- 24 Dec 2009 New trial record